RNS Number : 9194I
Ultrasis PLC
26 November 2008
Ultrasis plc
PRESS RELEASE
November 26 2008
Key contract win for Ultrasis in London
Ultrasis plc is pleased to announce that two primary care trusts in London have commissioned Beating the Blues for their patients.
The Hounslow Primary Care Trust (PCT) and Hammersmith & Fulham PCT contracts are both for three years and have a collective value of £360,000.
It will see the National Institute for Health and Clinical Excellence ('NICE') guidance on computerised cognitive behavioural therapy for depression being met in full across these areas with both PCTs offering Beating the Blues in all GP practices.
Nigel Brabbins CEO at Ultrasis said: 'We are delighted to be working with these two PCTs to implement Beating the Blues and increasing access to treatment for patients with mild and moderate depression through their GP practices.
'This is a significant development within the London SHA and a model we are confident other PCTs will follow.'
Ends
Editors Notes:
Ultrasis plc is a healthcare company with core expertise in health, psychology, software development and programme management. The Company delivers computerised healthcare products to the NHS, the corporate sector and other healthcare providers in the UK and internationally.
Ultrasis was the first company to offer computerised products based on Cognitive Behavioural Therapy (CBT) and interactive multimedia, and is the world leader in this field. The products help people tackle stress, anxiety and depression, and a full spectrum of related chronic conditions.
Beating the Blues is an eight-week, web-based treatment programme for depression based on CBT. Following a rigorous examination by the NICE 'Beating the Blues' was approved by NICE in February 2006 for use in the National Health Service.
On 28 March 2007 the Secretary of State for Health announced a framework agreement for the use of CBT in the NHS and approved 'Beating the Blues', saying: 'Computer-based therapy for milder, but more common mental health conditions such as depression and anxiety should be made available to any patients in England who could benefit from it from April 2007.'
www.ultrasis.com
www.thewellnessshop.co.uk
For further information please contact:
Nigel Brabbins
CEO
E-Mail: ultrasis@ultrasis.com
Telephone: +44 (0) 20 7566 3900
Fax: +44 (0) 20 7253 5313
Geoff Nash
FinnCap
Nominated Adviser and Joint Broker
Telephone: +44 (0) 20 7600 1658
John Webb
Marshall Securities
Joint Broker
+44 (0) 207 490 3788
Karen White/Sarah Rice
JBP Public Relations
E-Mail: karen@jbp.co.uk, sarah@jbp.co.uk
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTILFVRLSLEFIT